05 April 2016

FDA approves Inflectra, a biosimilar to Remicade


01 April 2016

Samsung Bioepis’ Flixabi® Infliximab Biosimilar

Recommended for Approval in the European Union


17 January 2016

Samsung Bioepis’ Benepali ® the First Fusion Protein Biosimilar
Approved by the European Commission


6 March 2015




16 February 2015

Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets



23 December 2014

FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration


22 December 2014

Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need



24 July 2014

FDA accepts Sandoz’s BLA application for filgrastim biosimilar


2 May 2014

Hospira states EPO approval via the 351k pathway is likely during 2016


30 April 2014

Cristália receives ANVISA approval for biosimilar production



21 March 2014

4th Biosimilars Conference

Boston, USA

What the future holds for biosimilar development and regulation



21 February 2014

France to allow biosimilar substitution


3 January 2014

FDA Accepts Lilly and Boehringer Ingelheim's NDA for Lantus Biosimilar



1 February 2013

Visiongain’s 12th Biosimilars Americas Conference held in Boston on April 15th - 17th 2013, The Seaport Hotel, Boston, USA


1 February 2013

Biosimilars and Follow-On Biologics 2013 Americas

Commercial, Regulatory and Technical Challenges Overcome

27th February - 1st March 2013, Hilton, Boston, Financial District, USA


1 February 2013

HansonWade’s Demonstrate Biosimilarity Summit

12-14 February 2013

Washington, D.C.


21 January 2013

Applications for new human medicines and biosimilars under evaluation by the Committee for Medicinal Products for Human Use



9 November 2012

EMA’s CHMP approves 1st Imatinib



August 30, 2012

FDA approves new treatment for severe neutroprnia in certain cancer patients


August 8, 2012

Amgen shutting down Epogen manufacturing in Longmont


July 9,2012

11th Annual Biosimilars UK
Strategic planning to maximize benefits in a complex regulatory and legal environment
29th - 31st October 2012, Visiongain Conference Centre, London UK


July 6, 2012

The Patient Protection and Affordable Care Act and the Biologics Price Competition and Innovation Act are upheld by the US Supreme Court creating an approval pathway for biosimilar and interchangable biological products while perserving the incentives that have fueled the development of said medicines


July 3, 2012

Southeast Asia Pharmaceutical Forum
Beyond BRICS Economies, the Next Opportunity in Pharmerging Markets
11 – 12 September 2012, Hilton Hotel, Singapore


March 13, 2012

Informa Life Sciences' 9th Annual Biosimilars Update: 23-24 May 2012, Prague, Czech Republic


March 13, 2012

FDA issues draft guidance on post approval drug safety


March 13, 2012

Paper calls for continued support for development of advanced therapies


February 9, 2012

FDA issues draft guidance on biosimilar development


January 6, 2012

EU to set biosimilar drug rules by mid-year


December 6, 2011

Drug industry applauds FDA plans for biosimilar review










Healthcare Economics has internationally respected consultants in sales/marketing, finance, business development, licensing and manufacturing within the biotechnology and pharmaceutical sectors.



The core competencies at Healthcare Economics include but are not limited to expert analysis of intellectual property, technology evaluations as well as forming strategic alliances.



Services provided such as early and late stage product acquisitions as well as maximizing market share are key deliverables that Healthcare Economics will contribute to your firm to sustain a continuum of steady and consistent growth.